Cell Therapy Human Raw Materials Market To Reach $ 11.44 Billion By 2030

Cell Therapy Human Raw Materials Market Growth & Trends

The global cell therapy human raw materials market size is expected to reach USD 11.44 billion by 2030 and is projected to expand at a CAGR of 22.32% from 2024 to 2030 according to a new report by Grand View Research, Inc. This is attributed to increasing investment in cell therapy research & development, growing number of clinical trials and rising adoption of regenerative & personalized medicines.

The field of cell therapy R&D has seen substantial growth in investments in recent years, fueling the development of next-generation treatments like CAR T-cell therapies. This surge in activity has advanced the understanding of cell biology, immunology, & gene editing, leading to the identification of novel therapeutic targets and the optimization of cell manufacturing processes. The improved understanding of the tumor microenvironment and immune system evasion mechanisms has enabled researchers to design CAR-T cells that effectively target and eliminate cancer cells. These advancements are being driven by increased funding in cancer immunotherapy research and are expected to propel the cell therapy raw materials market. For instance, in August 2023, Cellares, a startup specializing in cell therapy production, secured an additional USD 255 million in funding as investors continued to invest heavily in the company. Bristol Myers Squibb is among the supporters of Cellares, which asserts that its manufacturing capabilities can outperform traditional Contract Development and Manufacturing Organization (CDMO) facilities.

Furthermore, the expanding landscape of clinical trials in the field of cell therapy has become a driving force influencing the cell therapy human raw materials market. As the number of clinical trials investigating the efficacy and safety of cell-based therapies continues to rise, the demand for specific raw materials essential to these trials is experiencing a considerable upswing.

However, ethical concerns in stem cell research restrain the cell therapy human raw materials market, shaping the landscape with unique challenges. One prominent ethical dilemma revolves around the use of human-derived materials, particularly stem cells, which raises issues regarding the source, consent, and potential exploitation. Obtaining these materials may involve ethical considerations related to embryonic stem cells, as their extraction typically involves the destruction of embryos, sparking debates on the moral status of the early human life involved.

 Request a free sample copy or view report summary: Cell Therapy Human Raw Materials Market Report

Cell Therapy Human Raw Materials Market Report Highlights

• The cell culture supplements segment dominated the product segment with a revenue share of 27.84% in 2023, owing to the rising demand for animal-free cell-based therapies

• The cell culture media segment is expected to grow at the fastest CAGR over the forecast period due to the advancements in cell culture media technology which focuses on development of specialized formulations

• Based on end use, the biopharmaceutical & pharmaceutical companies segment dominated the market in 2023. On the other hand, the CROs & CMOs segment is expected to witness the fastest growth over the forecast period

• North America region dominated the market owing to factors such as the presence of key market players like Thermo Fisher Scientific, Inc, Actylis, ACROBiosystems and the growth in pharmaceutical & biotechnology research sectors in this region

• Asia Pacific is expected to register the fastest growth over the forecast period due to several companies expanding their presence in regions like Japan

Cell Therapy Human Raw Materials Market Segmentation

Grand View Research has segmented global cell therapy human raw materials market based on the model and service, end-use, application, and region:

Cell Therapy Human Raw Materials Product Outlook (Revenue, USD Billion, 2018 - 2030)

• Cell Culture Media

• Cell Culture Sera

• Cell Culture Supplements

  • Proteins

  • Growth Factors

  • Nucleotides

  • Other Supplements

• Reagents & Buffers

• Other Raw Materials

Cell Therapy Human Raw Materials End-Use Outlook (Revenue, USD Billion, 2018 - 2030)

• Biopharmaceutical & Pharmaceutical Companies

• CROs & CMOs

• Academic & Research Institutions

Cell Therapy Human Raw Materials Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • U.K.

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Cell Therapy Human Raw Materials Market

• Thermo Fisher Scientific, Inc

• Merck KGaA

• Actylis

• ACROBiosystems

• STEMCELL Technologies

• Grifols, S.A.

• Charles River Laboratories

• RoosterBio, Inc.

• PromoCell GMBH

• Danaher

• BioIVT

• GeminiBio

• Akron Biotech

• AllCells

• CGT Global